mice that lack all secondary lymphoid organs. In these mice, antibody secreting cells recognizing multivalent antigens were also observed in the bone marrow following an intravenous microbial challenge. These data suggest that newly formed B cells mature into IgD hi B cells simultaneously in the spleen and the bone marrow, and establish in a stringent manner that humoral immune responses can be initiated in situ in the bone marrow.
Introduction
Newly formed B cells emigrate from the bone marrow and home initially to the spleen 1 where they mature via transitional stages primarily into long-lived follicular B cells, and where they also differentiate into marginal zone (MZ) B cells. [2] [3] [4] [5] [6] [7] Naïve follicular B cells express high levels of surface IgD and CD23, and have the ability to recirculate, entering and exiting follicular niches in secondary lymphoid organs in search of antigen. 8, 9 While mature B cells have long been described in the bone marrow, 10, 11 our recent studies suggest that the bone marrow may provide an alternative perisinusoidal niche for follicular phenotype IgD hi B cells, wherein they have ready access to blood-borne pathogens and can thus contribute to Tindependent IgM responses directed against such organisms. 12 These studies describing bone marrow antibody-secreting cells generated in response to blood-borne pathogens were performed on splenectomized mice, but it remained formally possible that the IgM plasma cells in the bone marrow observed in these circumstances could have migrated to the bone marrow from some other secondary lymphoid organ.
Immature B cells in the bone marrow acquire the ability to migrate via the blood specifically to the spleen, presumably because these cells receive inhibitory signals that attenuate their ability to respond to chemokines and to thus home to lymph nodes or inflammatory sites. 13 The unique architectural organization of the spleen is important for MZ B cell development and survival, 5, 14 and the evolutionary requirement for immature B cells to home to this organ may be linked to the need for such cells to differentiate into MZ B cells. However the teleological rationale for mature follicular B cell maturation to apparently occur only in the spleen, as is generally assumed to be the case, is unclear. It is reasonable to entertain the possibility that B Aiolos, CD22, and CD72 for instance, all lose mature B cells in the bone marrow but preserve their phenotypic counterparts in other conventional secondary lymphoid organs. [15] [16] [17] [18] [19] The above null mice lack distinct negative regulators of the BCR. Mice lacking VCAM-1 also lack B cells in the bone marrow, 20, 21 suggesting that VCAM-1 may contribute to entry into or retention within this compartment. Although it has been suggested that CD22 might facilitate homing to the bone marrow by recognizing α2, 6 linked sialic acid containing ligands on the endothelium, 22 this proposed mechanism seems unlikely to be important since B cells expressing mutant CD22 that cannot bind α2, 6 linked sialic acid have been shown to home to the bone marrow as efficiently as wild type B cells. 23 A potential common link bringing together some of these mutant mice is an enhancement in BCR signal strength, but why such an augmentation of antigen receptor signaling may contribute to the loss of IgD hi bone marrow B cells remains unclear. In order to begin to explore the genetic regulation of mature B cell loss in the bone marrow it is important to determine whether maturation of these cells might occur in this compartment itself, since this maturation process, distinct from a parallel process occurring in the spleen, could possibly be influenced by specific mutations. Genetic defects linked to 
Continuous Bromodeoxyuridine (BrdU) labeling
Continuous labeling with BrdU (Sigma) was performed as described earlier. 25 Briefly 0.25 mg/ml of BrdU and 2 mg/ml of glucose was administered in drinking water for 22 days, and the decay in labeling was followed for 4 weeks after cessation of BrdU administration. The
BrdU decay data curves were generated by the least squares nonlinear regression analysis method using MacCurveFit 1.5 (Kevin Raner Software, Australia).
Pulse Bromodeoxyuridine (BrdU) labeling
Pulse labeling was achieved by administering a single intraperitoneal injection of BrdU (5 mg in one ml.), followed by the analysis of bone marrow and peripheral B cell populations.
Antibodies, staining and flow cytometry (FCM)
The following murine monoclonal antibody conjugates were used: Allophycocyanin (APC) and cy-chrome-RA3-6B2 (anti-CD45R/B220, rat IgG 2a , κ , fluorescein isothiocyanate Flow cytometry was performed using standard methodology as described elsewhere. 25, 26 Intracellular staining to detect BrdU incorporated into DNA was performed as described earlier. 25 Absolute number calculations were made as described before.
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The cytometers used were: Epics Elite ESP and FC500 (both Coulter Corp.), MoFlo (DakoCytomation), and FACSAria and LSR II (both from Beckton, Dickinson, San Jose, CA).
Gates in the spleen were set according to Hardy et al., 8 and Cariappa et al., 12 and the gates in the bone marrow were set according to Li et al., 27 Hendriks et al., 28 and Cariappa et al. 12 Processed samples were analyzed using Epics Elite, and RXP (both from Beckman Coulter) and FloJo v8.1.1 (Treestar Inc.) analysis software.
Bacterial challenge studies
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From 8 These were performed as described in an earlier study. 12 Briefly, 0.5 x 10 6 bacteria derived from an overnight culture of S.typhimurium strain SL3261 29 were injected intravenously into mice housed in a BL2 facility.
ELISPOT Assays
ELISPOT assays were performed as described earlier 12 using Salmonella flagellin (2.5 g/ml, a kind gift from Dr. Bobby J. Cherayil at MGH), and lipopolysaccharide from Salmonella typhimurium (LPS, 50 g/ml, List Biological Laboratories, Campbell, CA).
Statistical analyses
P-values for differences between groups were determined by the Mann-Whitney U test using StatView version 5.0.1. For the BrdU decay data points, curves of best fit by the least squares method were generated using MacCurveFit 1.5 (Kevin Raner Software, Australia).
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Results

Transitional B cells in the bone marrow
We have delineated B cell populations using IgM, IgD, and CD21 or by using these markers in combination with the AA4.1 antibody. We initially confirmed that newly 
Bone marrow and splenic B cells mature contemporaneously
To ask if mature bone marrow B cells are generated in situ contemporaneously with the maturation of B cells in the periphery, we injected mice with a single dose of BrdU which primarily labels cycling pro-B and pre-B cells in a transient manner, and dissipates extremely rapidly as these cells differentiate (data not shown). Further differentiation of these pulse-labeled cells was systematically followed by flow cytometric analysis of lymphocytes over an 8-day period in the bone marrow and the spleen (Figure 2A) , as well as for 5 days in blood, lymph nodes, and peritoneum ( Figure 2C ). Our goal in these studies was to use a spike of BrdU incorporation in cycling cells as a marker to follow the short term in vivo differentiation of a cohort of pulse-labeled B cells. This approach was not designed to examine half-lives. Robust labeling of pro-B cells was noted in the bone marrow, and up to 50% of all pro-B cells (Table I and see below), and distinct peaks of bone marrow and splenic mature B cells were sequentially labeled following the pulse. Table I shows that a single pulse of BrdU effectively labeled a large proportion of cells in the bone marrow and this labeling approach appears to be a valid method for following a cohort of cells.
We observed a major peak of BrdU labeled immature IgM + IgD neg (Fraction E) cells in the bone marrow at day 2 (Table I) Though our BrdU studies confirmed that NF/T1 cells mainly travel from the bone marrow to the spleen, and not to lymph nodes (Figure 2 ), we recognized that it is formally possible that NF/T1 cells could perhaps mature in other peripheral lymphoid organs, and then return to the bone marrow. In order to more rigorously test this possibility, we studied two mutant mice that lack peripheral lymphoid tissue, lymphotoxin alpha (LTα) deficient and aly/aly animals. LTα -/-mice lack lymph nodes and Peyer's patches, and are known to be permissive for B cell maturation. [36] [37] [38] We first established that BM B cell maturation was normal in the LTα -/-mice. As seen in Figure 3 , the examination of B cells using AA4. (Figure 3, bottom row) . These data supported the notion that the bone marrow contains transitional B cells and represents a distinct site of B cell maturation.
In order to establish that mature bone marrow B cells mature in situ and that the transitional B cells observed in the bone marrow do not represent cells that had migrated from the spleen, we splenectomized mutant mice, and examined B lineage cells in the bone marrow.
We waited to perform analyses at least two weeks after splenectomy to ensure that transitional cells of recent splenic origin, which have a half-life of around 4 days, could be excluded as a source of any transitional B cells observed in the bone marrow. 35 As can be seen in Figure Aly/aly mice carry an inherited homozygous mutation in the NFκB inducing kinase (NIK) gene whose product is required for activating the alternate pathway of NFκB activation downstream of the lymphotoxin β receptor and the BAFF receptor. 39 These mice lack lymph nodes and Peyer's patches, 24 and are known to be permissive for B cell maturation, albeit in a somewhat diminished fashion. 40, 41 We examined the bone marrow of aly/aly mice thirty days after removal of the spleen. As seen in Figure 4B , B cells mature in non-splenectomized and splenectomized aly/aly mice in a fashion similar to that observed in their heterozygous counterparts. Even though aly/aly mice have diminished B cell production, they nevertheless still generate transitional B cells in the bone marrow in the absence of the spleen. The presence As seen in Figure 5A , when splenectomized wild type mice or splenectomized LTα -/-mice were challenged intravenously with a vaccine strain of Salmonella typhimurium (SL3261), 
Discussion
These studies indicate that IgD hi B cells normally mature contemporaneously in the bone marrow and the spleen. They also formally establish that B cells in the bone marrow can be activated by blood borne microbes in the absence of all secondary lymphoid organs.
One approach that we used to examine B cell maturation in the bone marrow was the pulse labeling of cycling cells in this organ followed by the tracking of these labeled cells as they differentiate in vivo. The second approach was to use markers that are known to identify recently generated B cells and to examine differentiation in the bone marrow in wild type mice, in mice that lack most secondary lymphoid organs (but still retain the spleen), and in mice which lack all secondary lymphoid organs. BrdU pulse labeling was used as a cohort labeling tool in order to One caveat of previous studies suggesting that bone marrow B cells may be activated by blood-borne pathogens was the failure to formally exclude the possibility that some B cell activation might occur in splenectomized wild type mice in lymph nodes and that this could be followed by the migration of these activated cells to the bone marrow 12 . By analyzing For
